Antiparasitic Efficacy in Canine Sarcoptic Mange: A Comparison Study

Abstract

Sarcoptic mange, caused by Sarcoptes scabiei var. canis, is a highly contagious and zoonotic ectoparasitic infestation affecting dogs worldwide. This study evaluated the occurrence of sarcoptic mange and compared the therapeutic efficacy of selamectin, sarolaner and ivermectin in affected dogs in and around Jabalpur, Madhya Pradesh, India. From May to October 2024, 269 dogs with dermatological affections suspected of sarcoptic mange were examined, with 13 dogs (4.83%) tested positive based on skin scrapings. Age-wise analysis revealed that young dogs (<1 year) exhibited a higher susceptibility to the condition (53.85%). Additionally, male dogs demonstrated a higher occurrence rate (61.54%) compared to females; however, this difference was not statistically significant. A therapeutic trial was conducted on 12 dogs diagnosed with S. scabiei infestations, divided into three treatment groups: Group 1 received ivermectin (0.4 mg/kg PO daily for 28 days), Group 2 received sarolaner (2 mg/kg PO on Day 0), and Group 3 received selamectin (6–12 mg/kg topical spot-on on Day 0). Dermatological signs and mite counts were monitored before and after treatment, including crusting, scaling, erythematous papules and pruritus. Mite counts significantly decreased in sarolaner (100%) and selamectin (100%) treated groups, compared to the ivermectin treated group (26.32%). Sarolaner and selamectin demonstrated superior efficacy in eliminating mites and resolving clinical signs. Sarolaner monthly oral administration and selamectin topical application provide practical, effective options for managing sarcoptic mange, especially for the generalized condition.